ApoA-I technology is recognized for its ability to transform the treatment
of cardiovascular disease
TSX Exchange Symbol: RVX
CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Resverlogix Corp.
("Resverlogix") (TSX:RVX) is pleased to announce today that the World
Economic Forum has selected Resverlogix as a winner of the very prestigious
Technology Pioneer Award in recognition of its NexVas(TM) Plaque Removal
program. Candidates for this award must be involved in the development of
life-changing technologies and have potential for long-term impact on
business and society.
"We are elated to receive this high-level recognition from such an
important leading global body as the World Economic Forum. This awareness
that our innovative technology could have such a dramatic positive impact
for society, as it relates to the future treatment of cardiovascular
disease (CVD), further validates the positive direction of our NexVas
technology," stated Mr. Donald McCaffrey, President, CEO & Co-Founder of
Resverlogix.
Resverlogix was selected because it is developing exceptionally
promising new molecules that increase the production of ApoA-l and high
density lipoprotein (HDL) for the treatment of atherosclerosis. According
to the World Health Organization, CVD is the number one cause of death
globally, an immense problem currently responsible for killing nearly 18
million people annually worldwide.
"I would like to offer Canada's sincere congratulations to Resverlogix
for winning this international award from the World Economic Forum," said
the Honourable Minister Jim Prentice, Minister of Industry. "Resverlogix is
doing some incredible work in advancing the treatment of atherosclerosis,
the major underlying cause of cardiovascular disease and this award is a
testament to Canada's world-class biopharmaceutical industry."
Dr. Norman Wong, M.D., Co-Founder of Resverlogix added, "Current
therapies have made significant strides in improving outcomes but are only
able to address 30 percent of the risk associated with CVD. Consequently
there exists a significant unmet medical need for a therapy to address the
remaining 70 percent of risk. The proven ability of our drug to increase
the production of ApoA-I and functional HDL, offers enormous potential to
address this critical unmet need and impact the leading killer in the
world".
The Technology Pioneers 2008 were nominated by the world's leading
venture capital and technology companies. The final selection from 273
nominees was made by a panel of leading technology experts appointed by the
World Economic Forum. To be selected as a Technology Pioneer, a company
must be involved in the development of life-changing technology innovation
and have potential for long-term impact on business and society. In
addition, it must demonstrate visionary leadership, show the signs of being
a long-standing market leader - and its technology must be proven. The
award winners are companies that have been identified as developing and
applying highly transformational and innovative technologies in the areas
of energy, biotechnology and health, and information technology. Previous
Technology Pioneers have included Business Objects, Gilead Sciences, Corel
Corporation, Encore Software, Google, Mozilla Corporation and Napster.
Only one of the Technology Pioneers 2008 is based in Canada while 23
companies are US-based. Israel and Switzerland each boast three; the United
Kingdom and Sweden two each; and France, Germany, India, the Netherlands
and Russia, one each. Technology Pioneers are nominated in three main
categories: Biotechnology/Health Energy/Environment, and Information
Technology.
"This year the World Economic Forum received a record number of
applications from companies around the world to become a Technology
Pioneer. From a highly competitive field, we are extremely pleased to have
a community that is using innovation and technology to dramatically affect
the way society and business operate and doing so in a markedly
collaborative manner. We are excited to welcome the Technology Pioneers
class of 2008 to the larger community of the World Economic Forum and we
are looking forward to the fruits that their collaboration will bring,"
said Peter Torreele, Managing Director of the World Economic Forum.
The entire list of Technology Pioneers and interviews with the CEOs of
the selected companies can be found here:
http://www.weforum.org/techpioneers/2008.
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by
dysfunction of the heart and blood vessels. CVD includes atherosclerosis
(especially coronary heart disease which can lead to heart attacks),
cerebrovascular disease (stroke), and hypertension (high blood pressure).
The underlying cause of most CVD is a gradual clogging of the arteries
(atherosclerosis) that supply blood to the heart, brain and other vital
organs.
The American Heart Association estimates that almost 80 million
American Adults have one or more types of cardiovascular disease. CVD
remains the number one killer of developed nations. Nearly 2,400 Americans
die each day from cardiovascular disease - that is 1 person will die every
36 seconds.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the body's natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport
of peripheral cholesterol including that of the vessel wall to the liver
for processing. In multiple human and animal studies over-expression or
repeated infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans.
About the World Economic Forum
The World Economic Forum is an independent international organization
committed to improving the state of the world by engaging leaders in
partnerships to shape global, regional and industry agendas.
Incorporated as a foundation in 1971, and based in Geneva, Switzerland,
the World Economic Forum is impartial and not-for-profit; it is tied to no
political, partisan or national interests. (http://www.weforum.org)
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary
focus which is to develop novel small molecules that enhance ApoA-I. These
vital therapies address the grievous burden of atherosclerosis and other
important diseases such as acute coronary syndrome, diabetes, Alzheimer's
and other vascular disorders. The Company's secondary focus is TGF-Beta
Shield(TM), a program that aims to address burgeoning grievous diseases,
such as cancer and fibrosis. Resverlogix Corp. trades on the Toronto Stock
Exchange (TSX:RVX). For further information please visit
http://www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
Notes to Editors:
- Go to http://www.weforum.org/techpioneers/2008 for the entire list of
Technology Pioneers and interviews with the CEOs of the selected
companies.
- Download print-quality high resolution photographs of the CEOs of the
selected companies at: http://www.pbase.com/forumweb/techpioneers2008
| |
SOURCE Resverlogix Corp.
 back to top
CONTACT:
Theresa Kennedy, VP, Corporate
Communications, Resverlogix Corp., Phone: (403) 473-5359, Fax:
(403) 256-8495, Email: Theresa@resverlogix.com; Sarah Zapotichny,
Manager, Investor Relations, Resverlogix Corp., Phone: (403)
254-9252, Fax: (403) 256-8495, Email: Sarah@resverlogix.com;
Website: http://www.resverlogix.com
| |
|
